Medicare AdvantagePrior AuthHigh impact
Cinvanti (aprepitant) emulsion (Revised)
Humana·Oncology, Palliative Care·Medicare Advantage
Effective date
Jan 1, 2020
We identified it
Jun 25, 2026
Summary
This is a revised Humana Medicare Advantage prior authorization policy for Cinvanti (aprepitant) IV emulsion for chemotherapy-induced nausea and vomiting prevention. The policy requires concomitant corticosteroid and 5HT3 antagonist use, limits coverage to highly or moderately emetogenic chemotherapy, and explicitly excludes concurrent use with other NK1 antagonists (IV Emend, oral Emend 150mg, Varubi, Akynzeo). The revision date of April 22, 2026 indicates this is a very recent update requiring immediate billing team attention.
Action Required
Immediately: Billing and prior authorization teams must verify this is the current policy version on Humana's website before processing any Cinvanti claims. By April 22, 2026: Update all billing system logic and prior authorization workflows to enforce the two mandatory criteria: (1) member must be on concurrent corticosteroid (dexamethasone) AND 5HT3 antagonist (ondansetron, dolasetron, palonosetron, or granisetron) unless contraindicated, and (2) chemotherapy must be highly emetogenic (HEC) or moderately emetogenic (MEC). Update billing system rules to REJECT claims and flag for denial if the exclusion criterion is met: concurrent use with IV Emend, oral Emend (150mg dose), Varubi, or Akynzeo. Providers and clinical staff must verify all supporting medications and chemotherapy type are documented in the medical record before submission. Update prior authorization request templates and checklist forms to require documentation of: concomitant corticosteroid and 5HT3 antagonist use, chemotherapy emetogenicity level (HEC or MEC), and confirmation of no contraindicated concurrent medications. Train front-desk staff to alert providers that claims without prior authorization will be denied by Humana Medicare Advantage. Route all denials related to missing criteria or exclusions to clinical review for appeal potential.